Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
FDA warning letter
Pharma
Akeso-Summit, BIOSECURE, Candid and more—Fierce Pharma Asia
Akeso and Summit's ivonescimab handily beat Keytruda in a China phase 3 study. The House passed the BIOSECURE Act. Candid emerged with $370 million.
Angus Liu
Sep 13, 2024 8:53am
Zydus hit with FDA warning letter flagging glass contamination
Sep 11, 2024 11:42am
Astellas, AstraZeneca, Glenmark and more—Fierce Pharma Asia
Sep 6, 2024 9:00am
EyePoint's Yutiq production lands in the FDA's crosshairs
Aug 27, 2024 4:07pm
FDA rebukes troubled Eugia production site with a warning letter
Aug 19, 2024 8:10am
Hengrui, Sanofi and Aslan—Fierce Pharma Asia
Jul 19, 2024 9:48am
